NO20052781L - Forbindelser og prosesser - Google Patents

Forbindelser og prosesser

Info

Publication number
NO20052781L
NO20052781L NO20052781A NO20052781A NO20052781L NO 20052781 L NO20052781 L NO 20052781L NO 20052781 A NO20052781 A NO 20052781A NO 20052781 A NO20052781 A NO 20052781A NO 20052781 L NO20052781 L NO 20052781L
Authority
NO
Norway
Prior art keywords
compound
formula
alkyl
group
dihydropyrimidine
Prior art date
Application number
NO20052781A
Other languages
English (en)
Other versions
NO330983B1 (no
Inventor
Mark Bailey
Lee Newton
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0229243A external-priority patent/GB0229243D0/en
Priority claimed from GB0303589A external-priority patent/GB0303589D0/en
Priority claimed from GB0318515A external-priority patent/GB0318515D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20052781L publication Critical patent/NO20052781L/no
Publication of NO330983B1 publication Critical patent/NO330983B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Fremgangsmåte for fremstilling av en forbindelse med formel. og mellomprodukter anvendelige deri, er tilveiebragt. Fremgangsmåten omfatter omsetning av en forbindelse med formel RCO-CH-E med en forbindelse med formel RCi nærvær av en forbindelse med formel R3Ft4N-C(=NH)NH2 og en katalysator, for derved å danne et dihydropyrimidin; og oksidasjon av dihydro-pyrimidinet, hvilket gir forbindelsen med formel (1). Rer H eller en alkylgruppe; Rer H, en alkyl- eller arylgruppe; Rog R4 er hver, uavhengig, H, alkyl eller aryl eller Rog Rer bundet og danner, sammen med nitrogenet som de er bundet til og danner en 5- til 7-leddet, heterocyklisk ring; E er H, en usubstituert alkylgruppe, en arylgruppe eller en elektrontiltrekkende gruppe; og Xog Xer hver, uavhengig, utgående grupper, eller Xog Xrepresenterer sammen =0.
NO20052781A 2002-12-16 2005-06-08 Fremgangsmate for fremstilling av pyrimidinderivater NO330983B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0229243A GB0229243D0 (en) 2002-12-16 2002-12-16 Compounds and process
GB0303589A GB0303589D0 (en) 2003-02-17 2003-02-17 Compounds and process
GB0318515A GB0318515D0 (en) 2003-08-07 2003-08-07 Compounds and process
PCT/GB2003/005359 WO2004054986A2 (en) 2002-12-16 2003-12-09 Process for the preparation of pyrimidine compounds

Publications (2)

Publication Number Publication Date
NO20052781L true NO20052781L (no) 2005-07-07
NO330983B1 NO330983B1 (no) 2011-08-29

Family

ID=32600665

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052781A NO330983B1 (no) 2002-12-16 2005-06-08 Fremgangsmate for fremstilling av pyrimidinderivater
NO20110366A NO20110366L (no) 2002-12-16 2011-03-10 Forbindelser og prosesser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20110366A NO20110366L (no) 2002-12-16 2011-03-10 Forbindelser og prosesser

Country Status (23)

Country Link
US (2) US7524955B2 (no)
EP (2) EP2088142A3 (no)
JP (2) JP4579821B2 (no)
KR (1) KR101060215B1 (no)
AR (1) AR042355A1 (no)
AT (1) ATE448209T1 (no)
AU (1) AU2003288443B2 (no)
BR (1) BR0317313A (no)
CA (1) CA2509344C (no)
CY (1) CY1110605T1 (no)
DE (1) DE60330050D1 (no)
DK (1) DK1578731T3 (no)
ES (1) ES2335279T3 (no)
HK (1) HK1080477A1 (no)
IL (1) IL168884A (no)
MX (1) MXPA05006425A (no)
MY (1) MY138051A (no)
NO (2) NO330983B1 (no)
NZ (1) NZ540722A (no)
PT (1) PT1578731E (no)
SI (1) SI1578731T1 (no)
TW (1) TWI322145B (no)
WO (1) WO2004054986A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR20030092446A (ko) * 2002-05-29 2003-12-06 주식회사 한국토종약초연구소 씨형 간염 활성 억제를 갖는 조릿대 추출물을 포함하는조성물
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8153791B2 (en) * 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
US8013153B2 (en) * 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
US8328569B2 (en) 2010-05-21 2012-12-11 Cooper Technologies Company Adapter for coupling a deadbreak bushing to a deadbreak arrestor elbow

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278001A (en) * 1965-02-02 1966-10-11 Charles C Andrews Bearing assembly for auger conveyors
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4689414A (en) * 1986-02-24 1987-08-25 E. R. Squibb & Sons, Inc. 2-(substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
WO1990003973A1 (en) 1988-10-06 1990-04-19 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
JP3197971B2 (ja) * 1993-03-01 2001-08-13 塩野義製薬株式会社 5−カルボアルコキシピリミジン誘導体の合成方法
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3200070B2 (ja) 1994-11-16 2001-08-20 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
DE19517186A1 (de) * 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
SK77398A3 (en) 1995-12-14 1999-02-11 Merck & Co Inc Process for making dihydropyrimidinones
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
SE9702563D0 (sv) * 1997-07-02 1997-07-02 Astra Ab Compounds
EP1003734A2 (en) 1997-08-05 2000-05-31 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
EP1193259A4 (en) * 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
PL211797B1 (pl) 1999-07-13 2012-06-29 Lonza Ag Sposób wytwarzania 2-amino-4-(4-fluorofenylo)-6-alkilopirymidyno-5-karboksylanu oraz nowe związki pośrednie i sposoby ich wytwarzania
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005063728A2 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
US8273878B2 (en) 2012-09-25
KR101060215B1 (ko) 2011-08-29
EP2088142A2 (en) 2009-08-12
CA2509344C (en) 2011-10-04
US20090264654A1 (en) 2009-10-22
NO20110366L (no) 2005-07-07
MXPA05006425A (es) 2005-08-19
ATE448209T1 (de) 2009-11-15
DE60330050D1 (de) 2009-12-24
US7524955B2 (en) 2009-04-28
WO2004054986A3 (en) 2004-12-02
IL168884A (en) 2011-01-31
WO2004054986A2 (en) 2004-07-01
JP2010248222A (ja) 2010-11-04
NZ540722A (en) 2008-03-28
JP2006515600A (ja) 2006-06-01
PT1578731E (pt) 2010-01-12
JP4579821B2 (ja) 2010-11-10
TW200418809A (en) 2004-10-01
KR20050085674A (ko) 2005-08-29
HK1080477A1 (en) 2006-04-28
WO2004054986A8 (en) 2005-07-21
TWI322145B (en) 2010-03-21
US20060052604A1 (en) 2006-03-09
EP1578731B1 (en) 2009-11-11
JP5318037B2 (ja) 2013-10-16
AU2003288443A1 (en) 2004-07-09
DK1578731T3 (da) 2010-02-15
CY1110605T1 (el) 2015-04-29
SI1578731T1 (sl) 2010-02-26
AU2003288443B2 (en) 2007-10-25
CA2509344A1 (en) 2004-07-01
BR0317313A (pt) 2005-11-08
NO330983B1 (no) 2011-08-29
EP2088142A3 (en) 2010-04-21
MY138051A (en) 2009-04-30
AR042355A1 (es) 2005-06-15
EP1578731A2 (en) 2005-09-28
ES2335279T3 (es) 2010-03-24

Similar Documents

Publication Publication Date Title
NO20052781L (no) Forbindelser og prosesser
Atwal et al. Substituted 1, 4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2-hetero-1, 4-dihydropyrimidines
CA2610105C (en) Process for the synthesis of organic compounds
TW359670B (en) Process for producing quinazolin-4-one derivatives
NO20060142L (no) Syklisk tertiaer aminforbindelse
TR200100238T2 (tr) Yeni sübstitüe edilmiş pirazol türevleri
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
NO20055226L (no) Fremgangsmate for fremstilling av N-substituerte 2-cyanopyrrolidoner
WO2004103977A3 (en) Process for the preparation of pyrimidine derivatives
ES2959967T3 (es) Procedimiento de preparación deN-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida
CN109336792A (zh) 一种4-甲基-n-苯基-n-(2-苯基烯丙基)苯磺酰胺类化合物的合成方法
MXPA04002653A (es) Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo.
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
DK1404642T3 (da) Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
YU64403A (sh) Postupak za pripremanje mezilata piperazin derivata
Mollet et al. Stereoselective synthesis of bicyclic tetrahydrofuran-fused β-lactams and their conversion into methyl cis-3-aminotetrahydrofuran-2-carboxylates
WO2004046151A3 (en) Porphyrin derivatives
KR20180118054A (ko) 의약품 합성용 중간체 화합물의 제조 방법
CO5200782A1 (es) Las rutas sinteticas eficientes para la preparacion de los inhibidores d ela proteasa del rinovirus y los intermedios claves
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
NO20055991L (no) Fremgangsmate for syntetisering av heterocykliske forbindelser
HUP0203384A2 (hu) Eljárás ketiminek előállítására
JP2011506323A5 (no)
EP1699794B1 (en) Process for the preparation of triazolopyrimidines

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees